Patients with symptomatic acute hepatic porphyria were found to be at greater risk of accessing long-term sick leave and disability pension compared with the general population, but were not shown to ...
Study results published in PLoS One strongly suggest machine learning can be an effective approach to identify patients who should receive a diagnostic biochemical test to screen for acute hepatic ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the 2019 ...
Please provide your email address to receive an email when new articles are posted on . LONDON — Long-term givosiran treatment provided sustained benefit and improved quality of life among patients ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today on Rare Disease Day announced the premiere of its new documentary, Two of ...
A team of researchers has discovered a molecular missing link that helps explain why fasting brings on acute attacks of the genetic disease hepatic porphyria, according to a new report in the 26 ...
—The acute hepatic porphyrias (AHP) are rare disorders that typically become apparent during adulthood and may have varied presentations. Most of these quiz questions are derived from recent ...
The patient voice is a powerful one when it comes to healthcare advocacy, and Alnylam has put together a new documentary that maps the often-difficult journey those suffering with acute hepatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results